At Servier, we are proud to continue pioneering the science of IDH inhibition. Learn more about IDH mutations in glioma from our Senior Director and Head of Biochemistry, Stefan Gross. https://ow.ly/MzKi50SWlzz
About us
Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients’ lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all. See our community guidelines here: https://www.servier.us/community-guidelines To report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us
- Website
-
https://www.servier.us/
External link for Servier Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Boston , MA
- Type
- Nonprofit
Locations
-
Primary
200 Pier Four Boulevard
Boston , MA 02210, US
Employees at Servier Pharmaceuticals
Updates
-
#ICYMI: Servier is expanding their neuroscience focused partnership with Aitia. This cooperation aims to leverage Aitia’s AI technology to advance scientific research. For more click here: https://ow.ly/h6zh50Tb9M7 #MovedByScience
-
This September, we join the global community in recognizing Blood Cancer Awareness Month. At Servier, we are committed to advancing research supporting patients and spreading awareness about blood cancers such as Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). Learn more here: https://ow.ly/ktGL50Tb9Gx
-
Because the presence of IDH mutations in acute myeloid leukemia (AML) can impact a patient’s prognosis and potential treatment plan, molecular profiling is critical to inform next steps. Learn more here: https://ow.ly/7J7750SWlO5
-
For people living with acute lymphoblastic leukemia (ALL), knowledge is power. Know the signs, symptoms, and risk factors: https://ow.ly/LniN50SXOFl
-
A glioma diagnosis may come with questions about what to expect. Our team developed My Glioma Guide to help answer some initial questions and provide resources along the way. Take a look: https://ow.ly/2PQ150SWln4
-
Stefan Gross, our Senior Director and Head of Biochemistry, shares the significance of achieving such a major milestone for people living with IDH-mutant glioma. Learn more: https://ow.ly/AoGh50SWVv2
servier.us
-
The resilience of patients and the dedication of the brain cancer community drive everything we do. Learn more about the first targeted therapy FDA approved for patients living with Grade 2 IDH-mutant glioma here: https://ow.ly/lVMB50SWXq5
servier.us
-
A glioma diagnosis is devastating for patients and their families. Their stories of strength and perseverance drive everything we do. Learn more about our commitment to advancing care for patients with IDH-mutant glioma: https://ow.ly/67K450SSYkv
servier.us